Диссертация (1140309), страница 20
Текст из файла (страница 20)
2014. Т. 65. № 5. — Р. 875-83.85.Nakabayashi M., Hayes J., Taplin M.E., Lefebvre P., Lafeuille M.H.,Pomerantz M., Sweeney C., Duh M.S., Kantoff P.W. Clinical predictors of survival inmen with castration-resistant prostate cancer: evidence that Gleason score 6 cancer canevolve to lethal disease // Cancer. 2013. Т. 119. № 16. — Р. 2990-8.86.National Comprehensive Cancer Network. Prostate Cancer. Version 1.2014// http: //www.nccn.org/professionals/physician_gls/pdf/prostate. 2014.87.Nelius T., Klatte T., de Riese W., Filleur S. Impact of PSA flare-up inpatients with hormone-refractory prostate cancer undergoing chemotherapy // Int UrolNephrol.
2008. Т. 40. № 1. — Р. 97-104.88.O'Donnell A., Judson I., Dowsett M., Raynaud F., Dearnaley D., MasonM., Harland S., Robbins A., Halbert G., Nutley B., Jarman M. Hormonal impact of the17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patientswith prostate cancer // Br J Cancer. 2004. Т. 90. № 12. — Р. 2317-25.89.Olbert P.J., Hegele A., Kraeuter P., Heidenreich A., Hofmann R., SchraderA.J. Clinical significance of a prostate-specific antigen flare phenomenon in patientswith hormone-refractory prostate cancer receiving docetaxel // Anticancer Drugs.
2006.Т. 17. № 8. — Р. 993-6.90.Osoba D., Tannock I.F., Ernst D.S., Neville A.J. Health-related quality oflife in men with metastatic prostate cancer treated with prednisone alone ormitoxantrone and prednisone // J Clin Oncol. 1999. Т. 17. № 6.
— Р. 1654-63.91.Paller C.J., Antonarakis E.S. Cabazitaxel: a novel second-line treatment formetastatic castration-resistant prostate cancer // Drug Des Devel Ther. 2011. Т. 5. — Р.117-24.11592.Parker C., Nilsson S., Heinrich D., Helle S.I., O'Sullivan J.M., Fossa S.D.,Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., HoskinP., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., BoehmerS., Dall'Oglio M., Franzen L., Coleman R., Vogelzang N.J., O'Bryan-Tear C.G.,Staudacher K., Garcia-Vargas J., Shan M., Bruland O.S., Sartor O., Investigators A.Alpha emitter radium-223 and survival in metastatic prostate cancer // N Engl J Med.2013.
Т. 369. № 3. — Р. 213-23.93.Payne A.H., Hales D.B. Overview of steroidogenic enzymes in the pathwayfrom cholesterol to active steroid hormones // Endocr Rev. 2004. Т. 25. № 6. — Р. 947-70.94.Petrylak D.P., Ankerst D.P., Jiang C.S., Tangen C.M., Hussain M.H., LaraP.N., Jr., Jones J.A., Taplin M.E., Burch P.A., Kohli M., Benson M.C., Small E.J.,Raghavan D., Crawford E.D. Evaluation of prostate-specific antigen declines forsurrogacy in patients treated on SWOG 99-16 // J Natl Cancer Inst. 2006. Т.
98. № 8. —Р. 516-21.95.Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jr., Jones J.A.,Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., Benson M.C., Small E.J.,Raghavan D., Crawford E.D. Docetaxel and estramustine compared with mitoxantroneand prednisone for advanced refractory prostate cancer // N Engl J Med. 2004. Т. 351.№ 15. — Р. 1513-20.96.Petrylak D.P., Vogelzang N.J., Budnik N., Wiechno P.J., Sternberg C.N.,Doner K., Bellmunt J., Burke J.M., de Olza M.O., Choudhury A., Gschwend J.E.,Kopyltsov E., Flechon A., Van As N., Houede N., Barton D., Fandi A., Jungnelius U.,Li S., de Wit R., Fizazi K. Docetaxel and prednisone with or without lenalidomide inchemotherapy-naive patients with metastatic castration-resistant prostate cancer(MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial // LancetOncol.
2015. Т. 16. № 4. — Р. 417-25.97.Pezaro C.J., Omlin A., Lorente D., Nava Rodrigues D., Ferraldeschi R.,Bianchini D., Mukherji D., Riisnaes R., Altavilla A., Crespo M., Tunariu N., de BonoJ.S., Attard G. Visceral disease in castration-resistant prostate cancer // Eur Urol. 2014.Т. 65. № 2. — Р. 270-3.11698.Pienta K.J. Preclinical mechanisms of action of docetaxel and docetaxelcombinations in prostate cancer // Semin Oncol.
2001. Т. 28. № 4 Suppl 15. — Р. 3-7.99.Pollen J.J., Shlaer W.J. Osteoblastic response to successful treatment ofmetastatic cancer of the prostate // AJR Am J Roentgenol. 1979. Т. 132. № 6. — Р. 92731.100. Pond G.R., Sonpavde G., de Wit R., Eisenberger M.A., Tannock I.F.,Armstrong A.J. The prognostic importance of metastatic site in men with metastaticcastration-resistant prostate cancer // Eur Urol. 2014.
Т. 65. № 1. — Р. 3-6.101. Rajagopalan K., Peereboom D., Budd G.T., Olencki T., Murthy S., ElsonP., McLain D., Bukowski R. Phase II trial of circadian infusion floxuridine (FUDR) inhormone refractory metastatic prostate cancer // Invest New Drugs. 1998. Т. 16. № 3.— Р. 255-8.102. Rathkopf D.E., Smith M.R., de Bono J.S., Logothetis C.J., Shore N.D., deSouza P., Fizazi K., Mulders P.F., Mainwaring P., Hainsworth J.D., Beer T.M., NorthS., Fradet Y., Van Poppel H., Carles J., Flaig T.W., Efstathiou E., Yu E.Y., HiganoC.S., Taplin M.E., Griffin T.W., Todd M.B., Yu M.K., Park Y.C., Kheoh T., Small E.J.,Scher H.I., Molina A., Ryan C.J., Saad F. Updated interim efficacy analysis and longterm safety of abiraterone acetate in metastatic castration-resistant prostate cancerpatients without prior chemotherapy (COU-AA-302) // Eur Urol.
2014. Т. 66. № 5. —Р. 815-25.103. Ross R.W., Xie W., Regan M.M., Pomerantz M., Nakabayashi M.,Daskivich T.J., Sartor O., Taplin M.E., Kantoff P.W., Oh W.K. Efficacy of androgendeprivation therapy (ADT) in patients with advanced prostate cancer: associationbetween Gleason score, prostate-specific antigen level, and prior ADT exposure withduration of ADT effect // Cancer.
2008. Т. 112. № 6. — Р. 1247-53.104. Ryan C. Association of radiographic progression-free survival (rPFS)adapted from Prostate Cancer Working Group 2 (PCWG2) consensus criteria(APCWG2) with overall survival (OS) in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC): results from COU-AA-302 // Ann Oncol. 2012. Т.23. № Suppl. 9, Abstr. 8940.117105. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de SouzaP., Fizazi K., Mainwaring P., Piulats J.M., Ng S., Carles J., Mulders P.F., Basch E.,Small E.J., Saad F., Schrijvers D., Van Poppel H., Mukherjee S.D., Suttmann H.,Gerritsen W.R., Flaig T.W., George D.J., Yu E.Y., Efstathiou E., Pantuck A., WinquistE., Higano C.S., Taplin M.E., Park Y., Kheoh T., Griffin T., Scher H.I., Rathkopf D.E.,Investigators C.-A.-.
Abiraterone in metastatic prostate cancer without previouschemotherapy // N Engl J Med. 2013. Т. 368. № 2. — Р. 138-48.106. Ryan C.J., Smith M.R., Fizazi K., Saad F., Mulders P.F., Sternberg C.N.,Miller K., Logothetis C.J., Shore N.D., Small E.J., Carles J., Flaig T.W., Taplin M.E.,Higano C.S., de Souza P., de Bono J.S., Griffin T.W., De Porre P., Yu M.K., Park Y.C.,Li J., Kheoh T., Naini V., Molina A., Rathkopf D.E., Investigators C.-A.-. Abirateroneacetate plus prednisone versus placebo plus prednisone in chemotherapy-naive menwith metastatic castration-resistant prostate cancer (COU-AA-302): final overallsurvival analysis of a randomised, double-blind, placebo-controlled phase 3 study //Lancet Oncol.
2015. Т. 16. № 2. — Р. 152-60.107. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., Wu G.Y.,Scheffler J.E., Salvati M.E., Krystek S.R., Jr., Weinmann R., Einspahr H.M.Crystallographic structures of the ligand-binding domains of the androgen receptor andits T877A mutant complexed with the natural agonist dihydrotestosterone // Proc NatlAcad Sci U S A. 2001. Т. 98. № 9. — Р. 4904-9.108. San Francisco I.F., DeWolf W.C., Rosen S., Upton M., Olumi A.F.Extended prostate needle biopsy improves concordance of Gleason grading betweenprostate needle biopsy and radical prostatectomy // J Urol. 2003. Т. 169.
№ 1. — Р.136-40.109. Sartor O., Cooper M., Weinberger M., Headlee D., Thibault A., TompkinsA., Steinberg S., Figg W.D., Linehan W.M., Myers C.E. Surprising activity of flutamidewithdrawal, when combined with aminoglutethimide, in treatment of "hormonerefractory" prostate cancer // J Natl Cancer Inst. 1994. Т. 86. № 3. — Р. 222-7.110. Savarese D.M., Halabi S., Hars V., Akerley W.L., Taplin M.E., GodleyP.A., Hussain A., Small E.J., Vogelzang N.J. Phase II study of docetaxel, estramustine,118and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a finalreport of CALGB 9780.
Cancer and Leukemia Group B // J Clin Oncol. 2001. Т. 19. №9. — Р. 2509-16.111. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., deWit R., Mulders P., Chi K.N., Shore N.D., Armstrong A.J., Flaig T.W., Flechon A.,Mainwaring P., Fleming M., Hainsworth J.D., Hirmand M., Selby B., Seely L., de BonoJ.S., Investigators A. Increased survival with enzalutamide in prostate cancer afterchemotherapy // N Engl J Med. 2012. Т. 367. № 13. — Р.
1187-97.112. Scher H.I., Jia X., Chi K., de Wit R., Berry W.R., Albers P., Henick B.,Waterhouse D., Ruether D.J., Rosen P.J., Meluch A.A., Nordquist L.T., Venner P.M.,Heidenreich A., Chu L., Heller G. Randomized, open-label phase III trial of docetaxelplus high-dose calcitriol versus docetaxel plus prednisone for patients with castrationresistant prostate cancer // J Clin Oncol. 2011. Т. 29. № 16. — Р. 2191-8.113.
Scher H.I., Kelly W.K. Flutamide withdrawal syndrome: its impact onclinical trials in hormone-refractory prostate cancer // J Clin Oncol. 1993. Т. 11. № 8.— Р. 1566-72.114. Schroder F.H. Progress in understanding androgen-independent prostatecancer (AIPC): a review of potential endocrine-mediated mechanisms // Eur Urol. 2008.Т. 53. № 6. — Р. 1129-37.115. Seruga B., Ocana A., Tannock I.F. Drug resistance in metastatic castrationresistant prostate cancer // Nat Rev Clin Oncol. 2011. Т. 8. № 1.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
